STACKD Research is educational—not medical advice. Disclaimer
Also known as: GLP-1 RA · Ozempic · Wegovy · Rybelsus
A GLP-1 receptor agonist (marketed as Ozempic, Wegovy, and Rybelsus) with robust clinical evidence for glycemic control and weight management. The molecule that mainstreamed this category and a reference point for understanding incretin-based approaches discussed in fitness communities.
Mimics GLP-1 signaling to slow gastric emptying, reduce appetite, and improve insulin secretion in a glucose-dependent manner.
Multiple large outcome and weight-management trials support efficacy for indicated uses. Cardiovascular outcome data exist for specific formulations and populations.
Approved pharmaceutical with known side-effect profile. Rapid weight loss can include lean mass; rebound after discontinuation is documented. Not educationally equivalent to unapproved research compounds.
Start with our in-house roundups—plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
2021 · human
STEP 1 showed clinically meaningful weight loss vs placebo.
2016 · human
SUSTAIN-6 reported cardiovascular outcome findings for semaglutide.
2023 · human
SELECT (N=17,604): 20% reduction in major cardiovascular events (HR 0.80) in people with obesity and prior CVD but no diabetes.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes—from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic